NCT00369031 - Safety Study Of Nasal HIV Vaccine Adjuvanted With LTK63 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

March 31, 2008

Conditions

HIV Infections

Interventions

BIOLOGICAL

Human Immunodeficiency Virus glycoprotein 140 (vaccine)

Human Immunodeficiency Virus glycoprotein 140 (vaccine) alone nasally

BIOLOGICAL

HIV glycoprotein 140 + Labile Toxin mutant LTK63 adjuvant

Human Immunodeficiency Virus glycoprotein 140 (vaccine) + Labile Toxin mutant LTK63 adjuvant nasally

BIOLOGICAL

Labile Toxin mutant LTK63 adjuvant

Labile Toxin mutant LTK63 adjuvant alone

Trial Locations (1)

St George's Vaccine Institute, London